Thursday , July 27 2017
Home / 2015 / December

Monthly Archives: December 2015

Benefits of Tight Control

Psoriasis, a type of autoimmune disease, afflicts more than 7.5 million Americans, causing itchy or sore patches of thick, reddened skin covered with silvery scales. While this disease is most likely to develop in people 15-25 years old, after about a decade of having psoriasis, some people also develop psoriatic …

Read More »

First Patient Dosed in Epizyme’s Program for Genetically Defined Solid Tumors

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapies for cancer patients, announced today that the first patient has been dosed in the phase 2 study of tazemetostat in adult patients with genetically defined tumors. The phase 1 dose escalation study in pediatric patients …

Read More »

Lixte Biotech Licenses its Lead Anti-Cancer Compound for Treatment HCC to Taipei Medical University

EAST SETAUKET, N.Y., Dec. 30, 2015 /PRNewswire/ — Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT) announced today that it has granted an exclusive license of its lead anti-cancer compound, LB-100, for treatment of hepatocellular carcinoma (HCC) in Asia to Taipei Medical University (TMU). LB-100 is not currently approved for treatment of HCC. …

Read More »

TapImmune’s Ovarian Cancer Vaccine Receives Orphan Drug Designation from the FDA

TapImmune, Inc. (TPIV), a clinical-stage immunology-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer & metastatic disease, announced today that it has received Orphan Drug Designation from the U.S. Food & Drug Administration’s Office of Orphan Products Development (OOPD) for …

Read More »

Agenus Acquires PhosImmune in $44.9 Million Deal

LEXINGTON, Mass.–(BUSINESS WIRE)–Agenus Inc. (NASDAQ: AGEN), an immunotherapy company developing innovative treatments for cancer, today announced that it has acquired privately-held PhosImmune Inc., a company that has discovered an entirely new portfolio of cancer neoantigens. The acquisition provides Agenus the ability to accelerate the development of new cancer vaccines and other …

Read More »

CDC Reviews Most Pressing Public Health Challenges of 2015 and Plans for 2016

ATLANTA, Dec. 28, 2015 /PRNewswire/ — In a digital press kit released today, CDC reviews the most pressing public health challenges of 2015 and previews plans for 2016. CDC has made significant strides combatting some of the biggest threats to Americans’ health, including infectious and chronic diseases. In 2015, CDC helped …

Read More »

Immune Pharmaceuticals Licenses Bispecific Antibody Technology from Atlante Biotech

NEW YORK, Dec. 28, 2015 /PRNewswire/ — Immune Pharmaceuticals Inc. (NASDAQ: IMNP) (“Immune”) a clinical-stage company developing novel therapies for the treatment of immuno-inflammatory diseases and cancer, today announced it has entered into an exclusive license with Atlante Biotech SAS, to the patents and know-how for a new format of bispecific …

Read More »

Baxalta and Momenta’s Humira Biosimilar Candidate Meets Primary Endpoint in PK Study

BANNOCKBURN, Ill. and CAMBRIDGE, Mass., Dec. 21, 2015 (GLOBE NEWSWIRE) — Baxalta Incorporated (NYSE:BXLT) and Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), today announced that M923 met the primary endpoint in a randomized, double-blind, three-arm, parallel group, single-dose study. The primary objective of the study was to evaluate the pharmacokinetics of M923 compared …

Read More »

Chimerix’s Lead Candidate Misses Primary Endpoint in Late-Stage Study

DURHAM, N.C., Dec. 28, 2015 (GLOBE NEWSWIRE) — Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced that its Phase 3 SUPPRESS trial of brincidofovir in patients undergoing hematopoietic cell transplantation (HCT) did not achieve its primary endpoint for the prevention …

Read More »